JP2002506444A - ファルネシルタンパク質トランスフェラーゼの新規n置換尿素インヒビター - Google Patents

ファルネシルタンパク質トランスフェラーゼの新規n置換尿素インヒビター

Info

Publication number
JP2002506444A
JP2002506444A JP50450299A JP50450299A JP2002506444A JP 2002506444 A JP2002506444 A JP 2002506444A JP 50450299 A JP50450299 A JP 50450299A JP 50450299 A JP50450299 A JP 50450299A JP 2002506444 A JP2002506444 A JP 2002506444A
Authority
JP
Japan
Prior art keywords
compound
hydrogen
alkyl
mmol
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50450299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506444A5 (enExample
Inventor
レミゼウスキー,ステイシー
ケイ. マラムス,アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2002506444A publication Critical patent/JP2002506444A/ja
Publication of JP2002506444A5 publication Critical patent/JP2002506444A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP50450299A 1997-06-17 1998-06-15 ファルネシルタンパク質トランスフェラーゼの新規n置換尿素インヒビター Ceased JP2002506444A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17
US08/877,049 1997-06-17
PCT/US1998/011507 WO1998057948A1 (en) 1997-06-17 1998-06-15 Novel n-substituted urea inhibitors of farnesyl-protein transferase

Publications (2)

Publication Number Publication Date
JP2002506444A true JP2002506444A (ja) 2002-02-26
JP2002506444A5 JP2002506444A5 (enExample) 2005-12-22

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50450299A Ceased JP2002506444A (ja) 1997-06-17 1998-06-15 ファルネシルタンパク質トランスフェラーゼの新規n置換尿素インヒビター

Country Status (14)

Country Link
EP (1) EP0989979A1 (enExample)
JP (1) JP2002506444A (enExample)
KR (1) KR20010013881A (enExample)
CN (1) CN1267291A (enExample)
AR (1) AR013094A1 (enExample)
AU (1) AU8253598A (enExample)
CA (1) CA2293706C (enExample)
CO (1) CO4940458A1 (enExample)
HU (1) HUP0002954A3 (enExample)
IL (1) IL133389A0 (enExample)
NZ (1) NZ501571A (enExample)
PE (1) PE82799A1 (enExample)
WO (1) WO1998057948A1 (enExample)
ZA (1) ZA985205B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005058823A1 (ja) * 2003-12-17 2007-07-12 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6777415B2 (en) * 2000-10-05 2004-08-17 George Q. Daley Methods of inducing cancer cell death and tumor regression
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
AU2014239542A1 (en) * 2013-03-15 2015-10-01 Araxes Pharma Llc Covalent inhibitors of KRas G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Rasの阻害剤をスクリーニングするための方法
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之2-經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質の阻害剤
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体kras、hrasまたはnrasの調節因子としてのキナゾリン誘導体
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
EP1380581A1 (en) * 1995-12-22 2004-01-14 Schering Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases
ID22156A (id) * 1996-09-13 1999-09-09 Schering Corp Turunan substitusi benzosikloheptapiridina yang berguna untuk menghambat fernesil protein transferase
JP2001500515A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの阻害に有用な化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005058823A1 (ja) * 2003-12-17 2007-07-12 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途

Also Published As

Publication number Publication date
WO1998057948A1 (en) 1998-12-23
HUP0002954A2 (hu) 2001-06-28
AU8253598A (en) 1999-01-04
CA2293706A1 (en) 1998-12-23
IL133389A0 (en) 2001-04-30
AR013094A1 (es) 2000-12-13
HUP0002954A3 (en) 2002-11-28
CN1267291A (zh) 2000-09-20
KR20010013881A (ko) 2001-02-26
CA2293706C (en) 2008-11-18
NZ501571A (en) 2002-02-01
CO4940458A1 (es) 2000-07-24
EP0989979A1 (en) 2000-04-05
PE82799A1 (es) 1999-08-26
ZA985205B (en) 1998-12-15

Similar Documents

Publication Publication Date Title
JP2002506444A (ja) ファルネシルタンパク質トランスフェラーゼの新規n置換尿素インヒビター
JP3095781B2 (ja) G−タンパク質機能の阻害および増殖性疾患の処置に有用な三環式アミドおよび尿素化合物
JP2999556B2 (ja) ファルネシルタンパク質トランスフェラーゼの阻害に有用な三環式化合物
US6399615B1 (en) Farnesyl protein transferase inhibitors
US6699872B2 (en) N-substituted urea inhibitors of farnesyl-protein transferase
JP2002504149A (ja) G−タンパク質機能の阻害および増殖性疾患の処置のために有用なカルボキシピペリジルアセトアミド三環式化合物(ファルネシルタンパク質トランスフェラーゼインヒビター)
JP3269636B2 (ja) ファルネシルタンパク質トランスフェラーゼインヒビターとして有用な三環式ケトアミド誘導体
JP2001500505A (ja) Fptインヒビターとして有用な三環式化合物
KR20010013822A (ko) 파르네실 단백질 트랜스퍼라제의 억제에 유용한벤즈피리도 사이클로헵탄 화합물
JP3258342B2 (ja) ファルネシルタンパク質トランスフェラーゼインヒビターとして有用なベンゾ(5,6)シクロヘプタピリジン化合物
US6071907A (en) Tricyclic compounds useful as FPT inhibitors
JP2002507192A (ja) ファルネシルタンパク質トランスフェラーゼの新規三環式スルホンアミドインヒビター
US6426352B1 (en) Sulfonamide inhibitors of farnesyl-protein transferase
JP2000513033A (ja) ファルネシルタンパク質トランスフェラーゼインヒビターとして有用なベンゾ(5,6)シクロヘプタピリジン環状尿素およびラクタム
JP3153555B2 (ja) ファルネシルタンパク質トランスフェラーゼのインヒビターとして有用な新規三環式n―シアノイミン
JP2002504151A (ja) ファルネシルタンパク質トランスフェラーゼの新規アミノオキシアミド三環式インヒビター
JP2002504150A (ja) ファルネシルタンパク質トランスフェラーゼの新規フェニル置換三環式インヒビター
JP2002504143A (ja) ファルネシルタンパク質トランスフェラーゼの阻害に有用な化合物
CZ84499A3 (cs) Substituované deriváty benzocykloheptapyridinu použitelné pro inhibici farnesylprotein transferasy
SK33299A3 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
JP2002504146A (ja) ファルネシルタンパク質トランスフェラーゼの阻害に有用なベンゾ(5,6)シクロヘプタ(1,2−b)ピリジン誘導体
MXPA99001110A (en) Novel tricyclic n-cyanoimines useful as inhibitors of farnesyl-protein transferase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090728